Fig. 6.

LCC-09 attenuates arthritis-induced mechanical hyperalgesia. a LCC-09 chemical structure. b Mice (n = 6) were intraperitoneally injected with LCC-09 (390 μg/kg), followed by a rota-rod test. c, d Mice were treated as in Fig. 1. After 4 weeks, mice were intraperitoneally injected once with doses of LCC-09 (a, 39, 390 μg/kg), then underwent mechanical behavioral tests with von-Frey filaments. c Time courses (n = 1 for each group). d PWT at 60 min (n = 6). ***p < 0.001 by one-way ANOVA. e–j For long-term treatments, 390 μg/kg LCC-09 or 3 mg/kg tofacitinib was intraperitoneally (e–h) or orally (i, j) administered weekly for 9 consecutive weeks. Mechanical tests were performed before (b) or after (60 min) compound injection every week from week 4. Data are mean ± SEM of total tested mice (n = 6 per group). *p < 0.5, **p < 0.01, ***p < 0.001, vehicle- (n = 6) vs LCC-09-treated (n = 6) before or at 60 min; #p < 0.5, ##p < 0.01, ###p < 0.001 LCC-09-treated at 60 min vs before by two-way ANOVA. Black arrows are CFA treatments and white arrows are LCC-09 treatments